Pure Global

Grafting of white blood cells, platelet machine and stem cell collection - Vietnam Registration 2402762ĐKLH/BYT-HTTB

Access comprehensive regulatory information for Grafting of white blood cells, platelet machine and stem cell collection in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2402762ĐKLH/BYT-HTTB. The authorized representative in Vietnam is CÔNG TY TNHH THIẾT BỊ Y TẾ TERUMO VIỆT NAM.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
2402762ĐKLH/BYT-HTTB
Registration Details
Vietnam MOH Registration: 2402762ĐKLH/BYT-HTTB
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Grafting of white blood cells, platelet machine and stem cell collection
VN: Kít gạn bạch cầu, tiểu cầu máy và thu nhận tế bào gốc
Risk Class TTBYT Loại C

Registration Details

2402762ĐKLH/BYT-HTTB

000.00.04.G18-220816-0010

Theo theo phụ lục

Theo phụ lục

Company Information

Technical Details

The Kit for Leukapheresis, Spectra Optia IDL and the collection of stem cells provides an interface between the patient and the automated blood cell separation system Spectra Optia, which is used in applications of blood component separation by machine for treatment. The Spectra Optia IDL Set Kit is designated to guide the blood components from the intervention site through the automated blood cell separation system Spectra Optia and back into the patient's body. Please refer to the User Manual of the automated blood cell separation system Spectra Optia for full information on the indications, contraindications, precautions, adverse reactions, clinical benefits, target patient population, and performance characteristics.

Dates and Status

Oct 02, 2024